Welcome to PharmaCadence Analytical Services. We are a provider of discovery and lead optimization analytical services to the pharmaceutical and bio-medical research and development community. With nearly 60 years of combined experience in the industry, the PharmaCadence team is securely positioned to help you achieve your bioanalytical goals and objectives.
|
PharmaCadence Analytical Services was founded in 2008 by analytical scientists who share a commitment to improving scientific understanding and treatment of human disease through the application of analytical chemistry.
|
Richard C. King, Ph.D.
Dr. King graduated from SUNY College of Environmental Science and Forestry at Syracuse University with a B. S. in Chemistry in 1986. He obtained his Ph.D. in Analytical Chemistry from Drexel University in 1994 under the direction of Dr. Kevin Owens. The subject of his doctoral thesis is "MALDI TOFMS Instrumentation and Mechanisms."
Dr. King joined the Department of Drug Metabolism at Merck Research Laboratories (located in West Point, Pennsylvania) in 1994 where he worked in Preclinical Drug Metabolism with responsibilities related to bioanalysis and new technology development and implementation. In the fall of 2008, Dr. King left Merck and co-found PharmaCadence Analytical Services, LLC, a drug discovery and analytical support CRO located in Hatfield, Pennslyvania.
Dr. King's research interests cover a number of key areas in quantitative analysis (through mass spectrometry) including: ion formation mechanisms, ion chemistry, data processing, separation science, and automation.
|
|
